Streamlined path from preclinical to clinical stage
Explore our industry-leading translational models of MASH & MASH-HCC
Gubra’s GAN DIO-MASH model has been top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our entire model portfolio to ensure a successful preclinical study and smooth transition to the clinical stage.
Meet us at the AASLD 2024
Download Gubra’s AASLD Posters
We are attending AASLD The Liver Meeting from November 14-19, 2024. You can download our posters and explore the clinical translatability of our GAN DIO-MASH model, as well as our other biopsy-confirmed models for MASH and MASH-driven HCC.
Standard Study Outlines
“
We are experts in bridging preclinical and clinical development.
MICHAEL FEIGH Vice President, Scientific Sales
Michael’s primary focus is on MASH, MASH-HCC, obesity and idiopathic pulmonary fibrosis (IPF). Michael provides customers with scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.
Let’s meet at the EASL 2024
Contact us
Gubra
Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650